Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aimmune enters $170mm loan agreement; gets $40mm up front

Executive Summary

Aimmune Therapeutics Inc. (immunotherapies for allergies) entered a $170mm loan agreement with an affiliate of KKR, the proceeds of which will fully fund commercialization of the company's peanut allergy immunotherapeutic AR101. Proceeds will also go towards continued pipeline development, including Phase II work on AR201 for egg allergy. The company drew down $40mm immediately. A further draw of $85mm could be released upon FDA approval of AR101, and the remaining $40mm will be available in 2020 under certain conditions.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies